Oncology · Medical Literature
The effect of Bach flower remedies on hope and quality of life in people with advanced cancer: a triple-blind randomized clinical trial.
Abstract
To evaluate the effect of Bach Flower Remedies Therapy on the hope and quality of life of people with advanced cancer. Randomized, triple-blind (1:1) clinical trial in a high-complexity public hospital in the Southern region of Brazil. Ninety-nine participants were allocated to either the intervention group (solution with nine flower essences) or the placebo group (Hydro-brandy solution). Both groups used four drops orally, four times a day, for 120 days, with monthly follow-up. Hope measured by the Herth Hope Index, quality of life through Functional Assessment of Chronic Illness Therapy - Palliative Care. In the flower remedies group (n = 50), hope varied from 43.44/48 to 44.53/48 and in the placebo group (n = 49) from 41.67/48 to 44.29/48, a significant increase over time (p = 0.024), with no difference between groups (p = 0.977). Quality of life ranged from 141.39/184 to 150.60/184 in the flower remedies group, and from 133.76/184 to 148.96/184 in the placebo group, with no significant difference between groups (p = 0.230) or time (p = 0.240). Although not statistically significant, there was a slight increase in life expectancy and quality of life, highlighting the importance of non-pharmacological therapies in evidence-based palliative care practice. RBR-8q6z6kq.
Clinical relevance
This trial addresses the growing demand for evidence-based non-pharmacological interventions in palliative oncology, specifically examining Bach Flower Remedies Therapy — a widely used but poorly studied complementary modality — in patients with advanced cancer. The study targets a vulnerable population for whom hope and quality of life are primary therapeutic goals when curative options are exhausted. Given the proliferation of complementary therapies in oncology practice, clinicians need rigorous trial data to counsel patients appropriately and avoid unsubstantiated recommendations.
Key findings
1. In a triple-blind RCT (1:1 allocation), 99 participants with advanced cancer were randomized to a nine-flower-essence solution (n = 50) or a hydro-brandy placebo (n = 49), administered as four drops orally four times daily for 120 days with monthly follow-up. 2. Hope, measured by the Herth Hope Index (HHI, scale 0–48), increased over time in both groups (flower remedies: 43.44 → 44.53; placebo: 41.67 → 44.29), reaching statistical significance across time (p = 0.024); however, there was no significant between-group difference (p = 0.977). 3. Quality of life, assessed via FACIT-Palliative Care (scale 0–184), showed a numerical increase in both groups (flower remedies: 141.39 → 150.60; placebo: 133.76 → 148.96), with no statistically significant between-group difference (p = 0.230) and no significant time effect (p = 0.240). 4. The magnitude of hope improvement was nearly identical between arms (Δ ≈ +1.09 in flower remedies vs. Δ ≈ +2.62 in placebo), suggesting the observed temporal gain in hope is attributable to non-specific or placebo effects rather than the active intervention. 5. No effect sizes, confidence intervals, or NNT/NNH values were reported in the abstract, limiting precise estimation of clinical meaningfulness. 6. The study was conducted in a high-complexity public hospital in Southern Brazil, which may limit generalizability to other healthcare settings and patient populations.
Practice implications
Based on this trial, Bach Flower Remedies Therapy cannot be recommended over placebo for improving hope or quality of life in advanced cancer patients, as no statistically significant between-group differences were demonstrated on either primary outcome. The observed within-group improvements in both arms over 120 days underscore the therapeutic value of structured, frequent patient contact and supportive follow-up — elements clinicians can intentionally incorporate into palliative care protocols regardless of the specific complementary modality used. Oncology and palliative care teams should communicate transparently with patients about the current lack of efficacy evidence for Bach Flower Remedies while continuing to prioritize validated non-pharmacological psychosocial interventions that carry stronger evidentiary support.